FOx BIOSYSTEMS receives €2,5 million EIC grant

Dec 20, 2022 | Katleen Vandersmissen

FOx BIOSYSTEMS is awarded an EIC* accelerator grant for their ambitious project to bring to market a combined quantification and isolation application for Extracellular Vesicles (EVs) unlocking their great potential in diagnostic applications.

FOx BIOSYSTEMS markets a versatile device for the life science industry using fiber-optic sensor probes to measure interactions between biomolecular particles. The use of these unique sensor probes facilitates fluidics-free Surface Plasmon Resonance (SPR) analyses of large particles in complex samples such as lysates or whole blood while completely eliminating the risk of clogging or cross-contamination.

Specifically, this technology allows, on a single device, the unbiased detection, quantification, characterization and isolation of exosomes or extracellular vesicles. This powerful and unique ability will greatly accelerate pre-clinical research and development of new diagnostic and treatment options in oncology, cardiology, and inflammation or neurodegenerative diseases.

The EIC grant will enable FOx BIOSYSTEMS to launch a collection of EV applications on their system to the market in 2024, three years sooner than previously planned. This will cover an array of application specific sensors, protocols, and workflow support with immediate potential impact on ongoing and new research programs.

“This grant is a clear validation of the urgent need for the benefits we offer to the fast-growing EV research market. It recognizes the unique potential value of our technology to obtain high quality and unbiased research data in this field."
      - Thomas Van Elzakker (CEO FOx BIOSYSTEMS)

Thomas Van Elzakker believes this will accelerate general access to the potential of EVs for early and specific diagnosis of many diseases, leading to better therapies, reducing the healthcare burden, and ultimately saving patient’s lives.

 * EIC: European Innovation Council


FOx BIOSYSTEMS is a Belgian company with a mission to revolutionize the life sciences and pharmacological research market with innovative real-time, label-free analysis products. The basis of their success is a novel fiber-optic-based SPR biosensor which enables users to generate high-quality, cost-effective biomolecular data fast, and over a wide range of applications. 

For more information visit

Join a Heran Fund

We are open to novel investments and are always planning the next funds and investment strategies. Leave your details below and our partners will be in touch.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Pitch your company

Submit your pitch below. We receive dozens of pitches each week and process these dilligently. We might not be able to get back to you immediately.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.